Heart & blood pressure · West Des Moines, IA
Heart and blood pressure studies in West Des Moines, IA
8 recruiting studies have a site in West Des Moines.
8 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics
- Location
- West Des Moines, IA + 64 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
Boston Scientific Corporation
- Location
- West Des Moines, IA + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Boehringer Ingelheim
- Location
- West Des Moines, IA + 91 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Boehringer Ingelheim
- Location
- West Des Moines, IA + 78 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- West Des Moines, IA + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
AstraZeneca
- Location
- West Des Moines, IA + 104 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Amgen
- Location
- West Des Moines, IA + 193 other US sites
- Eligibility basics
- Ages 50–105
- RecruitingPhase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Anthos Therapeutics, Inc.
- Location
- West Des Moines, IA + 131 other US sites
- Eligibility basics
- Ages 65+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.